CNBX Stock Analysis
CN
Uncovered
CNBX Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
CNBX Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate, Cannabics SR, is an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for colorectal cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. It is focused on Phase I/II (a) clinical studies for Cannabics SR and RCC-33. It also has several other drug candidates under development, including PLP-33, BRST-33, MLN-33 and PRST-33.